Abstract
An important issue in allogeneic peripheral blood progenitor cell transplantation is the optimization of the regimen of mobilization of progenitor cells from normal donors. It has been shown that for G-CSF doses up to 10 μg/kg/day, a dose–response relationship exists for the degree of progenitor cell mobilization. Formal comparisons with doses higher than 10 μg/kg/day, however, have not been reported. The aim of this study was to compare the mobilization and collection results of two different G-CSF (Filgrastim) schedules: 10 μg/kg/12 h (n = 20; group A) vs 10 μg/kg/24 h (n = 20; group B). Apheresis sessions were started on day 5 (after 4 days of G-CSF). Adverse events consisted of bone pain, headache, and fatigue which required treatment with acetaminophen ± codeine in both donor groups. Discontinuation of G-CSF administration for intolerable side-effects was not necessary in any case. The increase in peripheral leukocyte and lymphocyte counts × 109/l on day 5 was higher in group A (56.2 (37.1–75.2) and 4.4 (2.1–14.6), respectively) than in group B (27.5 (13.2–53.9) and 2.6 (1.9–5.1), respectively) (P < 0.0001 and P = 0.008). Platelets × 109/l decreased in group A from 228 (161–286) before G-CSF administration to 207 (155–328) on day 5 (P = 0.03), whereas no change was observed in group B. Following the first apheresis, a significant decrease in platelet count was observed with both G-CSF schedules without any differences between groups. The number × 106/kg of both nucleated and CD34+ cells collected after the first apheresis session was higher in group A (672 (462–992) and 5.9 (3.4–10.4), respectively) than in group B (427 (319–608) and 3.1 (1.1–6.8), respectively) (P = 0.0003 in both cases). The median number of CD3+cells × 106/kg collected after one apheresis session was similar with both G-CSF schedules (212 (91–430) in group A and 170 (110–291) in group B) (P = NS). In conclusion, the schedule of 10 μg/kg/12 h was well tolerated and resulted in the collection of a higher number of progenitor cells than 10 μg/kg/24 h without increasing the T cell content. This approach could avoid the donor having to undergo a second apheresis, and facilitate further graft manipulation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martínez, C., Urbano-Ispizua, A., Marín, P. et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant 24, 1273–1278 (1999). https://doi.org/10.1038/sj.bmt.1702073
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702073
Keywords
This article is cited by
-
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects
Investigational New Drugs (2014)
-
Novel agents and approaches for stem cell mobilization in normal donors and patients
Bone Marrow Transplantation (2012)
-
Pegfilgrastim overdose: case report and review of the literature
Medical Oncology (2011)
-
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
Annals of Hematology (2010)
-
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
Annals of Hematology (2010)